X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The funding will be used to support the Phase III clinical development of dexpramipexole. It is an eosinophil maturation inhibitor that will be used in the treatment of Eosinophilic Asthma.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viking Global Investors
Deal Size: $425.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 13, 2024
Details:
Dexpramipexole dihydrochloride inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. It is being developed for moderate-to-severe eosinophilic asthma.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
KNS-760704 (dexpramipexole), a selective inhibitor of eosinophil maturation, in Phase 2 Exhale trial change in FEV1 was correlated with change in blood absolute eosinophil count, demonstrating the link between eosinophil depletion and clinical benefit.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
The EXHALE trial was a randomized, double-blind, placebo-controlled trial of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) ≥300/µL.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
The EXHALE trial was a randomized, double-blind, placebo-controlled study of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) ≥300/µL.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
In hypereosinophilic syndrome, dexpramipexole has previously been shown in a Phase 2 trial to significantly reduce requirements for oral corticosteroids and in a subset of patients to produce durable disease remission.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
Details:
Primary endpoint was achieved, with dexpramipexole demonstrating a statistically significant reduction in blood eosinophil count over 12 weeks.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
The multi-center Phase 2 trial is a randomized, double-blind, placebo-controlled study to evaluate the effects of three dose levels of oral dexpramipexole for 12 weeks.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
